High-Flow Nasal Cannula, a Boon or a Bane for COVID-19 Patients? An Evidence-Based Review.
Abhishek SinghPuneet KhannaSoumya SarkarPublished in: Current anesthesiology reports (2021)
HFNC is considered an aerosol-generating intervention with the risk of viral aerosolization with a concern of potential nosocomial transmission of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2). However, there is no consensus regarding the use of HFNC in novel coronavirus-infected pneumonia (NCIP). HFNC seems to be an effective and safe treatment modality in acute respiratory failure with optimal settings and selection of ideal patients.
Keyphrases
- respiratory failure
- sars cov
- respiratory syndrome coronavirus
- extracorporeal membrane oxygenation
- mechanical ventilation
- end stage renal disease
- chronic kidney disease
- randomized controlled trial
- ejection fraction
- escherichia coli
- peritoneal dialysis
- liver failure
- drug resistant
- risk assessment
- climate change
- patient reported outcomes
- human health